Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Core Viewpoint - Azitra, Inc. has received approval from NYSE American for its compliance plan to meet continued listing standards after previously being notified of non-compliance due to insufficient stockholders' equity [1][2]. Group 1: Compliance and Listing Status - Azitra must regain compliance with the NYSE American listing standards by April 1, 2027, or face potential delisting proceedings [2]. - The company will remain listed on NYSE American during the compliance plan period and will undergo periodic reviews, including quarterly monitoring [3]. - Receipt of the notice from the Exchange does not immediately affect the listing or trading of Azitra's common stock [4]. Group 2: Company Overview and Programs - Azitra is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a rare skin disease [5]. - The ATR-12 program includes a Phase 1b clinical trial in adult patients, while the ATR-04 program addresses EGFR inhibitor-associated rash and has received Fast Track designation from the FDA [5]. - Azitra's proprietary platform includes a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning for drug development [5].